A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Trial Profile

A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Cobiprostone (Primary)
  • Indications Portal hypertension
  • Focus Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals
  • Most Recent Events

    • 16 Mar 2016 Status changed from completed to discontinued, according to ClinicalTrials.gov record.
    • 30 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top